Aviado · Research
Longevity Daily
Thursday, August 6, 2026
Listen
Today's Brief
Today's standout stories share one theme: midlife decisions are the primary lever for brain longevity. Our must-read finds optimal vascular health between 45 and 65 adds nearly 13 dementia-free years — echoed by a companion study naming hypertension, diabetes, and smoking as three risks worth 12 years of cognitive freedom. On the drug front, semaglutide's Phase 3 EVOKE trial failed to slow Alzheimer's, while a new immune-checkpoint antibody passed Phase 1 with early neuroprotection signals. P&G's $3.8 billion acquisition of Thorne is the supplement industry's clearest signal yet that longevity has gone mainstream.
10 stories1 peer-reviewed2 trials1 Aviado original
Cognitive Health & Neuroprotection
Optimal Midlife Vascular Health Adds Nearly 13 Dementia-Free Years
A large longitudinal study finds that people with ideal cardiovascular health between ages 45 and 65 gain nearly 13 additional dementia-free years compared to those with poor vascular profiles. The researchers tracked blood pressure, cholesterol, blood glucose, and other markers over decades — showing the brain keeps a long ledger for damage done in midlife. This isn't about exotic interventions: the gains come from the fundamentals longevity-focused readers already know — controlling blood pressure, managing glucose, and staying active. If you're in your 40s or 50s, your vascular choices right now are among the most powerful investments in your cognitive future.
Read more →A Novel Immune-Checkpoint Antibody Passes Phase 1 in Alzheimer's — With Early Neuroprotection Signals
IBC-Ab002, an anti-PD-L1 immunotherapy designed to reverse immune system aging, has cleared its Phase 1 safety threshold in Alzheimer's patients and shown early reductions in neuronal damage biomarkers. The approach is fundamentally different from amyloid-clearing therapies: rather than targeting plaques, it aims to rejuvenate the body's immune defenses so the brain can protect itself. As a Phase 1 study with a small cohort, safety is the primary headline — but the mechanism represents one of the most genuinely novel hypotheses entering the Alzheimer's pipeline.
Read more →Semaglutide Fails Phase 3 Alzheimer's Trial — Despite Years of Promising Signals
Despite observational data showing semaglutide users had 40–70% lower rates of first-time Alzheimer's diagnosis, the randomized Phase 3 EVOKE trial found the GLP-1 drug did not meaningfully slow disease progression. The trial was rigorous — long treatment durations, MRI imaging, and CSF biomarkers — making the null result hard to dismiss. This matters for anyone banking on semaglutide or tirzepatide as cognitive protection: the epidemiological signal likely reflects selection bias, not a neuroprotective drug effect.
Read more →Supplements & Compounds
Protein Quality, Not Just Quantity, Shapes Aging — And Methionine May Be the Key Amino Acid
New research in Cell Metabolism shows that adding moderate methionine supplementation to a low-protein, Mediterranean-style diet activates a hormone cascade — GH, GLP-1, and FGF21 — that reduces body fat and frailty without caloric restriction. The finding may explain why plant-rich diets promote longevity while sometimes compromising physical robustness: they are often low in this one sulfur amino acid. The practical upshot is nuanced: it is less about cutting all protein and more about optimizing amino acid composition, particularly for those on plant-forward eating patterns.
Read more →Research & Papers
Mayo Clinic: Personalized Senolytic Therapy May Rejuvenate Aging Bone
Emerging research from Mayo Clinic indicates that senolytic drugs — compounds that selectively clear senescent 'zombie' cells — can rejuvenate bone tissue and improve skeletal health in aged preclinical models. The team is developing personalized protocols targeting individual bone aging profiles, with potential implications for osteoporosis and age-related fracture risk. Human applications remain investigational, but the findings add bone health to an expanding list of aging conditions where senolytics show meaningful preclinical promise.
Read more →Just How Much Does Chronic Inflammation Drive Aging? New Evidence Points to 'A Lot'
A new analysis of longitudinal epidemiological data finds that chronic low-grade inflammation — so-called inflammaging — functions as one of the most powerful independent predictors of age-related decline and mortality, separable from other aging mechanisms. Individuals in the highest inflammatory burden quartile show measurably faster biological deterioration across multiple organ systems. The practical implication is direct: anti-inflammatory lifestyle strategies — quality sleep, Mediterranean-style diet, consistent exercise, and stress management — are not peripheral optimizations but central mechanisms in the longevity toolkit.
Read more →Aviado Research: Navigating the Longevity Evidence Landscape
Aviado Research's latest review synthesizes emerging evidence across key longevity mechanisms, offering practical frameworks for health optimization grounded in primary literature. The analysis is designed to help readers cut through the noise and calibrate their protocols with greater precision. Read the full analysis for the complete findings and recommendations.
Read the full Aviado analysis →Lifestyle & Nutrition
Avoid These Three Midlife Risk Factors and Add 12 Dementia-Free Years
A new study finds that avoiding high blood pressure, type 2 diabetes, and smoking between ages 45 and 65 is associated with living 12 additional years free of dementia. The finding reinforces that dementia onset is not fixed — midlife remains one of the highest-leverage windows for intervention. For readers who have already addressed these risk factors, the data is reassuring; for those who haven't, 12 years of cognitive freedom is one of the most compelling arguments for action in recent memory.
Read more →Industry & Policy
From Mice to 'Gym Rats': The Unregulated Peptide Boom Draws Alarm from Scientists
A Los Angeles Times investigation finds consumer demand for experimental peptides — compounds like BPC-157, TB-500, and growth hormone secretagogues — has exploded over the last decade, driven by social media hype and widespread distrust of public health guidance. Researchers warn that most of these compounds were never tested in humans at therapeutic doses, and that contaminated or mislabeled products from grey-market suppliers pose real, underappreciated risks. The piece lands as the FDA simultaneously tightens compounding pharmacy rules and faces pressure from practitioners to expand legitimate access.
Read more →Procter & Gamble to Acquire Supplement Giant Thorne for $3.8 Billion
P&G has agreed to acquire Thorne, the practitioner-channel supplement brand known for its clinical-grade formulations, for $3.8 billion — the most significant supplement acquisition in recent memory. The deal pulls Thorne into one of the world's largest consumer goods companies, extending a wave of strategic acquisitions reshaping the vitamins, minerals, and supplements category. For longtime Thorne customers and clinicians, the central question is whether a mass-market parent will maintain the rigorous quality standards and product transparency that set Thorne apart from conventional retail brands.
Read more →